How to Move Forward After a Thumbs Down from FDA

Interview with Kevin Sidow, Former CEO and President of Moximed

In late 2016, I was able to sit down with Kevin Sidow. At the time, he was President & Chief Executive Officer for Moximed, and had been since 2008.

Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.

Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.

Interview Highlights with Kevin Sidow

  • How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.

  • What makes the Atlas System different than other orthopedic knee implants.

  • How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.

  • How Kevin and his team responded when their device received an unfavorable response from an FDA panel.

  • Kevin’s approach to financing a medtech startup after raising nearly $100M to fund Moximed.

  • Kevin’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self.

Premium Members Only

Premium Members Only

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You May Like These Articles

Medsider Premium

Become a premium member and unlock access to exclusive Medsider benefits.

Medsider Mentors

Medsider Mentors

Medsider Playbooks

Medsider Playbooks

Playbook

A Guide to Widespread Adoption in Medtech

In medtech, developing novel, impactful technology is often just the starting line. The real race begins when you try to integrate your solution into the often-resistant healthcare system – a hurdle that has tripped up countless promising companies. Here are the key strategies and lessons from five veterans in the medtech space on how to overcome this hurdle.

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest